High rate of extended-spectrum beta-lactamase-producing gram-negative infections and associated mortality in Ethiopia: a systematic review and meta-analysis.
Antimicrobial resistance
ESBL
Gram-negative bacteria
Multidrug-resistance
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
08 08 2020
08 08 2020
Historique:
received:
19
03
2020
accepted:
14
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
13
7
2021
Statut:
epublish
Résumé
Extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria have become a serious threat to global health. Their rapid spread is associated with high mortality due to ineffective antibiotic treatment. To date a regular surveillance of multidrug-resistant (MDR) pathogens in Ethiopia is not established. For this report, published data regarding ESBL-producing bacteria in different health facilities of Ethiopia were reviewed. This study collates data from published information on the rates and clinical implications of infection with ESBL-producing Gram-negative bacteria in Ethiopia. A systematic literature search was conducted using PubMed, PubMed Central, Medline, Science Direct and Google scholar from October 2018 to March 2019. Eligible studies were identified by applying quality criteria. The pooled proportion of ESBL-producing Gram-negative bacteria was estimated based on a random effect model. The publication bias and the variation in proportion estimates attributed to heterogeneity were assessed. Fourteen studies with relevant data were included in the review. In total, 1649 Gram-negative bacteria isolated from 5191 clinical samples were included. The pooled proportion estimate of ESBL-producing Gram-negative bacteria was 50% (95% CI: 47.7-52.5%. Data showed a high level of heterogeneity (I In this meta-analysis, the pooled prevalence of ESBL-producing pathogens is alarmingly high. Data on mortality rates is scarce. This highlights the need for establishing and upgrading clinical microbiology laboratories in Ethiopia for routine antibiotic susceptibility testing and extended surveillance of multidrug resistance.
Sections du résumé
BACKGROUND
Extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria have become a serious threat to global health. Their rapid spread is associated with high mortality due to ineffective antibiotic treatment. To date a regular surveillance of multidrug-resistant (MDR) pathogens in Ethiopia is not established. For this report, published data regarding ESBL-producing bacteria in different health facilities of Ethiopia were reviewed.
METHODS
This study collates data from published information on the rates and clinical implications of infection with ESBL-producing Gram-negative bacteria in Ethiopia. A systematic literature search was conducted using PubMed, PubMed Central, Medline, Science Direct and Google scholar from October 2018 to March 2019. Eligible studies were identified by applying quality criteria. The pooled proportion of ESBL-producing Gram-negative bacteria was estimated based on a random effect model. The publication bias and the variation in proportion estimates attributed to heterogeneity were assessed.
RESULTS
Fourteen studies with relevant data were included in the review. In total, 1649 Gram-negative bacteria isolated from 5191 clinical samples were included. The pooled proportion estimate of ESBL-producing Gram-negative bacteria was 50% (95% CI: 47.7-52.5%. Data showed a high level of heterogeneity (I
CONCLUSIONS
In this meta-analysis, the pooled prevalence of ESBL-producing pathogens is alarmingly high. Data on mortality rates is scarce. This highlights the need for establishing and upgrading clinical microbiology laboratories in Ethiopia for routine antibiotic susceptibility testing and extended surveillance of multidrug resistance.
Identifiants
pubmed: 32771059
doi: 10.1186/s13756-020-00782-x
pii: 10.1186/s13756-020-00782-x
pmc: PMC7414654
doi:
Substances chimiques
Anti-Bacterial Agents
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Commentaires et corrections
Type : ErratumIn
Références
Sci Rep. 2019 Mar 12;9(1):4224
pubmed: 30862858
Biomed Res Int. 2018 Mar 26;2018:9519718
pubmed: 29780833
Can J Infect Dis Med Microbiol. 2018 Dec 13;2018:4846159
pubmed: 30651898
Antimicrob Resist Infect Control. 2019 Feb 15;8:39
pubmed: 30815254
Antimicrob Resist Infect Control. 2016 May 14;5:18
pubmed: 27186369
East Afr J Public Health. 2012 Jun;9(2):58-61
pubmed: 23139958
J Clin Diagn Res. 2013 Oct;7(10):2173-7
pubmed: 24298468
Rev Inst Med Trop Sao Paulo. 2009 Jul-Aug;51(4):211-6
pubmed: 19739001
Crit Care. 2016 Jul 11;20(1):221
pubmed: 27417949
J Glob Infect Dis. 2010 Sep;2(3):263-74
pubmed: 20927289
Zoonoses Public Health. 2018 Nov;65(7):766-776
pubmed: 29984468
PLoS One. 2015 Dec 15;10(12):e0144944
pubmed: 26670718
J Med Assoc Thai. 2014 Mar;97 Suppl 3:S35-45
pubmed: 24772579
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Acta Trop. 2005 Aug;95(2):143-8
pubmed: 15993831
Antimicrob Agents Chemother. 2010 Sep;54(9):3564-8
pubmed: 20547788
Infect Drug Resist. 2017 Jan 25;10:27-34
pubmed: 28182124
BMC Infect Dis. 2017 Mar 1;17(1):180
pubmed: 28249575
Emerg Infect Dis. 2014 Mar;20(3):434-41
pubmed: 24564906
Front Microbiol. 2013 Jul 11;4:188
pubmed: 23874325
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:90-103
pubmed: 18154532
J Infect Dev Ctries. 2011 Feb 01;5(1):23-33
pubmed: 21330737
Int J Infect Dis. 2013 Dec;17(12):e1255-8
pubmed: 24176550
BMC Res Notes. 2010 Dec 24;3:348
pubmed: 21184671
J Infect. 2007 Sep;55(3):254-9
pubmed: 17574678
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
J Pharm (Cairo). 2018 Sep 9;2018:5070742
pubmed: 30271652
BMC Infect Dis. 2018 Oct 20;18(1):524
pubmed: 30342476
BMC Res Notes. 2017 Sep 6;10(1):448
pubmed: 28877761
J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2-iii78
pubmed: 29514274
Antimicrob Resist Infect Control. 2012 Feb 14;1(1):11
pubmed: 22958833
Int J Microbiol. 2017;2017:3183076
pubmed: 28270849
Nature. 1965 Oct 16;208(5007):239-41
pubmed: 5326330
PLoS One. 2019 Apr 15;14(4):e0215177
pubmed: 30986262
PLoS One. 2016 Nov 15;11(11):e0166519
pubmed: 27846254
PLoS One. 2016 Aug 30;11(8):e0161685
pubmed: 27574974
J Clin Microbiol. 2005 Feb;43(2):745-9
pubmed: 15695674
BMC Res Notes. 2018 Aug 31;11(1):629
pubmed: 30170613
Antimicrob Resist Infect Control. 2018 Nov 19;7:138
pubmed: 30479751